(Q39511426)

12 September 2017

title

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research (English)

1 reference

12 September 2017

1 reference

ChEBI release 2020-05-28

Silvio E Perea

1

1 reference

12 September 2017

Idania Baladron

2

1 reference

12 September 2017

Yanelda Garcia

3

1 reference

12 September 2017

Yasser Perera

4

1 reference

12 September 2017

Adlin Lopez

5

1 reference

12 September 2017

Jorge L Soriano

6

1 reference

12 September 2017

Noyde Batista

7

1 reference

12 September 2017

Aley Palau

8

1 reference

12 September 2017

Ignacio Hernández

9

1 reference

12 September 2017

Hernán Farina

10

1 reference

12 September 2017

Idrian Garcia

11

1 reference

12 September 2017

Lidia Gonzalez

12

1 reference

12 September 2017

Jeovanis Gil

13

1 reference

12 September 2017

Arielis Rodriguez

14

1 reference

12 September 2017

Margarita Solares

15

1 reference

12 September 2017

Agueda Santana

16

1 reference

12 September 2017

Marisol Cruz

17

1 reference

12 September 2017

Matilde Lopez

18

1 reference

12 September 2017

Carmen Valenzuela

19

1 reference

12 September 2017

Osvaldo Reyes

20

1 reference

12 September 2017

Pedro A López-Saura

21

1 reference

12 September 2017

Carlos A González

22

1 reference

12 September 2017

Alina Diaz

23

1 reference

12 September 2017

Lila Castellanos

24

1 reference

12 September 2017

Aniel Sanchez

25

1 reference

12 September 2017

Lazaro Betancourt

26

1 reference

12 September 2017

Vladimir Besada

27

1 reference

12 September 2017

Luis J González

28

1 reference

12 September 2017

Hilda Garay

29

1 reference

12 September 2017

Roberto Gómez

30

1 reference

12 September 2017

Daniel E Gómez

31

1 reference

12 September 2017

Daniel F Alonso

32

1 reference

12 September 2017

Phillipe Perrin

33

1 reference

12 September 2017

Jean-Yves Renualt

34

1 reference

12 September 2017

Hugo Sigman

35

1 reference

12 September 2017

Luis Herrera

36

1 reference

12 September 2017

Boris Acevedo

37

1 reference

12 September 2017

publication date

7 July 2011

1 reference

Molecular and Cellular Biochemistry

12 September 2017

published in

1 reference

12 September 2017

volume

356

1 reference

12 September 2017

issue

1-2

1 reference

12 September 2017

page(s)

45-50

1 reference

New strategies in chronic myeloid leukemia

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

One-thousand-and-one substrates of protein kinase CK2?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Protein kinase CK2: a newcomer in the 'druggable kinome'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Joining the cell survival squad: an emerging role for protein kinase CK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Genome-wide expression screens indicate a global role for protein kinase CK2 in chromatin remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Protein kinase CK2: signaling and tumorigenesis in the mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Multiple myeloma cell survival relies on high activity of protein kinase CK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Protein kinase CK2 in human diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Protein kinase CK2 as a druggable target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Emergence of protein kinase CK2 as a key target in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Features and potentials of ATP-site directed CK2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Association of nonribosomal nucleolar proteins in ribonucleoprotein complexes during interphase and mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11010-011-0950-Y

Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

21 January 2018

1 reference

12 December 2020

Targeting tyrosine kinases in cancer: the second wave

1 reference

12 December 2020

Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids

1 reference

12 December 2020

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy

1 reference

12 December 2020

10.1007/S11010-011-0950-Y

Identifiers

DOI

1 reference

release_zqaebb4abbg55e6agyug74mfva

12 September 2017

Fatcat ID

0 references

1 reference